Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash from Operations (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Cash from Operations readings, the most recent being 466000.0 for Q4 2025.

  • Quarterly Cash from Operations rose 75.61% to 466000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9145000.0 through Dec 2025, down 8.71% year-over-year, with the annual reading at 9145000.0 for FY2025, 8.71% down from the prior year.
  • Cash from Operations hit 466000.0 in Q4 2025 for Oramed Pharmaceuticals, up from 1625000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2076000.0 in Q2 2024 and bottomed at 11199000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 4137950.0, with a median of 3384000.0 recorded in 2021.
  • Peak annual rise in Cash from Operations hit 178.82% in 2024, while the deepest fall reached 923.2% in 2024.
  • Oramed Pharmaceuticals' Cash from Operations stood at 6903000.0 in 2021, then decreased by 16.79% to 8062000.0 in 2022, then skyrocketed by 82.41% to 1418000.0 in 2023, then tumbled by 34.77% to 1911000.0 in 2024, then soared by 75.61% to 466000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Cash from Operations are 466000.0 (Q4 2025), 1625000.0 (Q3 2025), and 3535000.0 (Q2 2025).